Physician profile
Eda Cengiz
NPI 1851581045
$67,743.66
in general payments reported to CMS, 2019-2025
13 companies · $24K in 2025
The $24K reported for 2025 was more than what 94% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,247 · 2020: $5,778 · 2021: $7,828 · 2022: $8,147 · 2023: $8,749 · 2024: $4,573 · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $26K · Travel and Lodging: $6,169 · Honoraria: $4,250 · Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,725.50 |
| Travel and Lodging | $6,168.69 |
| Honoraria | $4,250.00 |
| Food and Beverage | $1,599.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36,397.59 | 2019-2025 | |
| Mannkind Corporation | $8,969.11 | 2020-2025 | |
| Eli Lilly and Company | $6,000.00 | 2021-2022 | |
| Tandem Diabetes Care, INC. | $3,727.72 | 2020-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Genzyme Corporation | $3,633.08 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $3,440.00 | 2020 | |
| Sanofi-Aventis U.S. LLC | $2,891.71 | 2025 | |
| Novo Nordisk As | $2,040.00 | 2022 | |
| Medtronic, INC. | $415.62 | 2024-2025 | Minimed 780g |
| Companion Medical, INC. | $141.77 | 2020 | |
| Abbott Laboratories | $48.67 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $23.77 | 2019 | |
| Biomarin Pharmaceutical INC. | $14.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eda Cengiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.